|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
4
|
|
gptkbp:bfsParent
|
gptkb:Gleevec
|
|
gptkbp:activities
|
tyrosine kinase inhibitor
|
|
gptkbp:approves
|
gptkb:2001
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:Gleevec
|
|
gptkbp:category
|
gptkb:D
not recommended
|
|
gptkbp:clinical_trial
|
Phase II
Phase III
Phase I
maintenance therapy
second-line treatment
first-line treatment
|
|
gptkbp:contraindication
|
severe liver impairment
hypersensitivity to imatinib
|
|
gptkbp:discovered_by
|
gptkb:Novartis
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:formulation
|
gptkb:software_framework
gptkb:tablet
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
imatinib mesylate
|
|
gptkbp:ingredients
|
C29 H31 N7 O2 S
|
|
gptkbp:interacts_with
|
gptkb:warfarin
CY P3 A4 inducers
CY P3 A4 inhibitors
|
|
gptkbp:is_used_for
|
gptkb:chronic_myeloid_leukemia
gptkb:gastrointestinal_stromal_tumors
|
|
gptkbp:lifespan
|
18 hours
|
|
gptkbp:manager
|
oral
|
|
gptkbp:marketed_as
|
gptkb:Europe
gptkb:Japan
gptkb:United_States
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:research
|
solid tumors
other cancers
myeloproliferative disorders
leukemias
lymphomas
|
|
gptkbp:side_effect
|
fatigue
nausea
diarrhea
rash
edema
|
|
gptkbp:storage
|
room temperature
protected from light
protected from moisture
|
|
gptkbp:targets
|
gptkb:BCR-ABL_fusion_protein
gptkb:PDGFR
gptkb:c-KIT
|
|
gptkbp:type_of
|
220127-57-1
|